Compare Ascendis Pharma A/S (ASND) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs NICE Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while NICE Ltd trades at $100.04 (market cap $5.87B). The key difference: Ascendis Pharma A/S is far larger — about 3× NICE Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | NICE | |
|---|---|---|
Market Cap | $17.74B | $5.87B |
Sector | Health | Technology |
52-Week High | $277.18 | $170.37 |
52-Week Low | $163.32 | $83.15 |
Enterprise Value | $18.11B | $5.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NICE trades at $99.74, up 1.92% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 11.82 suggesting potential undervaluation. Recent news highlights expansion in AI-powered customer experience solutions, including partnerships and AWS integration, driving positive sentiment.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include competitive pressures in the software sector and potential margin compression as revenue growth moderates. Institutional ownership trends and bullish analyst ratings support a favorable investment case, though market volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
